Attovia Therapeutics, Inc. (ATTO)
| Market Cap | 854.56M |
| Revenue (ttm) | 1.35M |
| Net Income | -64.13M |
| EPS | -15.89 |
| Shares Out | 43.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 98,155 |
| Open | 19.12 |
| Previous Close | 19.18 |
| Day's Range | 18.20 - 19.94 |
| 52-Week Range | 16.15 - 22.79 |
| Beta | 1.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 15, 2022 |
About ATTO
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobuli... [Read more]
Financial Performance
Financial StatementsNews
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for i...
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, ...
Attovia opens at $21.00, IPO priced at $17.00
Attovia (ATTO) priced 17M shares at $17.00. The deal size was increased to 17M shares of common stock from 12.5M shares. The deal priced at the top of the $15.00-$17.00…
Attovia indicated to open at $20, IPO priced at $17
11:43 EDT Attovia (ATTO) indicated to open at $20, IPO priced at $17
Attovia indicated to open at $24, IPO priced at $17
Attovia (ATTO) priced 17M shares at $17.00. The deal size was increased to 17M shares of common stock from 12.5M shares. The deal priced at the top of the $15.00-$17.00…
Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering
SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for i...
Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO
Biopharmaceutical company Attovia Therapeutics said on Tuesday it was targeting a valuation of $731.5 million in its upsized initial public offering, signaling strong demand for biopharma listings.
Attovia Therapeutics Appoints John W. Smither to Board of Directors
Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sector Mr. Smither brings extensive public company board and audit committee experience in the bio...
Biopharmaceutical company Attovia Therapeutics files for US IPO
Biopharmaceutical company Attovia Therapeutics on Tuesday filed for an initial public offering in the United States.
Attovia Therapeutics
Attovia Therapeutics has filed to go public with an IPO on the NASDAQ